Muhammet Korkusuz, Nuh Kumru, Saliha Yarımoğlu, Tayfun Et, Rafet Yarımoğlu

Şiddetli Covid-19 Tedavisinde İntravenöz İmmünglobulin Kullanımı: 3 Hastalık Olgu Sunumu

COVID-19’a bağlı gelişen hiperinflamatuvar yanıtın kesin bir tedavisinin henüz bulunamamış olmasına rağmen, yüksek doz kortikosteroid, interlökin reseptör blokerleri ve intravenöz immünoglobulin (IVIG) tedavisi bugünlerde kullanılmaktadır. Biz bu makalemizde, yoğun bakımımızda IVIG tedavisi uyguladığımız 3 Covid-19 hastasındaki tecrübelerimizi paylaşmayı amaçladık.

The Use of Intravenous Immunoglobulin for the Treatment of Severe Covid-19: Case Presentation for Three Patients

Although the treatment of the hyperinflammatory response due to COVID-19 has not yet been found, high-dose corticosteroids, interleukin receptor blockers and intravenous immunoglobulin (IVIG) are used to improve the hyperinflammatory response. In this article, we aimed to share our experiences with 3 patients who received IVIG therapy in ICU.

PDF

___

1. Jolles S, Sewell WAC, MisbaH SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1- 11. https://doi.org/10.1111/j.1365-2249.2005.02834.x
2. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins inimmunodeficiencies: More than mere replacement therapy. Clin Exp Immunol. 2011;164:2-5. https://doi.org/10.1111/j.1365-2249.2011.04387.x
3. SamsonM, Fraser W, Lebowitz D. Treatments for Primary Immune Thrombocytopenia: A Review. Cureus. 2019;11:e5849. https://doi.org/10.7759/cureus.5849
4. Galeotti C, Kaveri SV, Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). Clin Transl Immunology. 2020;9:e1198. https://doi.org/10.1002/cti2.1198
5. T.C. Sağlık Bakanlığı. Erişim tarihi: 21.12.2020. Erişim adresi: https://covid19.saglik.gov.tr/TR-66341/antisitokin-antiinflamatuar-tedaviler-koagulopati-yonetimi. html
6. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695-703. https://doi.org/10.1038/nrmicro974
7. Xie Y, Cao S, Dong H, ve ark. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81:318-56. https://doi.org/10.1016/j.jinf.2020.03.044
8. Herth FJF, Sakoulas G, Haddad F. Use of intravenous immunoglobulin for thetreatment of COVID-19: retrospective case series. Respiration. 2020;99:1145-53. https://doi.org/10.1159/000511376
9. Khanna N, Widmer AF, Decker M, ve ark. Respiratory syncytial virüs infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008;46:402-12. https://doi.org/10.1086/525263
10. Wang JT, Sheng WH, Fang CT, ve ark. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis. 2004;10:818-24. https://doi.org/10.3201/eid1005.030640
11. Arabi YM, Arifi AA, Balkhy HH, ve ark. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160:389-97. https://doi.org/10.7326/M13-2486
12. Prabagar MG, Choi H, Park J, Loh S, Kang Y. Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute. Clin Exp Med. 2014;14:361-73. https://doi.org/10.1007/s10238-013-0255-4
13. Kim MS, An MH, Kim WJ, Hwang T. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 2020;17:e1003501. https://doi.org/10.1371/journal.pmed.1003501